| 发明名称 | Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists | ||
| 摘要 | The present invention provides a method for optimizing levels of mifepristone in a patient suffering from a mental disorder amenable to treatment by mifepristone. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1300 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1300 ng/mL. | ||
| 申请公布号 | US8921348(B2) | 申请公布日期 | 2014.12.30 |
| 申请号 | US201314065792 | 申请日期 | 2013.10.29 |
| 申请人 | Corcept Therapeutics, Inc. | 发明人 | Belanoff Joseph K. |
| 分类号 | A61K31/56;G01N33/49;A61K31/575 | 主分类号 | A61K31/56 |
| 代理机构 | Kilpatrick Townsend & Stockton LLP | 代理人 | Kilpatrick Townsend & Stockton LLP |
| 主权项 | 1. A method for optimizing levels of mifepristone in a patient suffering from a disorder amenable to treatment by mifepristone, the method comprising: treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1300 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1300 ng/mL. | ||
| 地址 | Menlo Park CA US | ||